Weekly thought on $AEMD, $CGC, $IBIO, $LRAD, $MMNFF, $SOLOW

Before you read on, please be aware that the analysis below is my opinion only and may include flawed assumptions and inaccuracy of logic; therefore, caveat emptor applies here.  Furthermore, all emphasis (color-coded, boldness, and underlined) on the excerpts are my own.

Whoa! As predicted from last week, the SP500 bounced nicely off the 79 & 89 MA supports. SP-500_weeklyEven after years of observing the price action around the 79 & 89 MA supports and resistances, I am still amazed by their consistency in maintaining supports and resistances. With China & U.S. ceasing fire in the tariffs war, the SP500 is already on fire in the after hour market.  The bull is BACK!

As to my portfolio, I added $CGC Jan 2020 call options as well as $MMNFF to get back into the cannabis sector.  I also added to $AEMD.

$CGC – Due to the volatility, I decided to just buy the Jan 2020 call options and forget about it.

$MMNFF – I had been waiting for the earnings release before taking a position because I expected the price to drop after earnings.  It did, and I bought.  MedMen Enterprises Inc has been called the “Starbucks” of pot retailers, so I figured I better get a piece of the pie before it takes off.

$AEMD –  This week Aethlon Medical’s Cancer Therapy Receives “Breakthrough Device” Designation from the U.S. Food and Drug Administration. This is terrific news!

Basically, Aethlon Medical’s hemopurifier medical device now has two breakthrough device designations:

  1. The Hemopurifier is a single-use device indicated for the treatment of life-threatening highly glycosylated viruses that are not addressed with an approved treatment
  2. The Hemopurifier is a single-use device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Therapy with the Hemopurifier device should be an adjunct to standard of care for cancer.

When you re-read the above two breakthrough device designations, you realize that Aethlon Medical’s hemopurifier is indeed a life-saver for those who are inflicted with the deadly viruses or the deadly metastatic cancer.  From the following article, “AEMD: Breakthrough Device Designation Granted for Cancer Therapy. Could Be Game-Changer for AEMD“, there is an excerpt below that highlighted the benefit of being assigned the breakthrough device designation: AEMD_breakthruDevice

In essence, by getting the Breakthrough Device designation, Aethlon Medical’s hemopurifier will be enjoying a much speedy response from the FDA.  In other words, AEMD’s hemopurifier will be enjoying the use of the “carpool lane” when seeking FDA response so to speak.

What I am more excited about is the fact that the Breakthrough Device designation will bring awareness of the hemopurifier to the patients with metastatic cancer.   By knowing about it, the patients can now apply to use the Aethlon Medical’s hemopurifier under the “right to try” law or the Expanded Access (Compassionate Use) as an adjunct to standard of care for metastatic cancer to see if they can be treated successfully.

I also expect to hear about the partnership with BPs’ chemotherapy soon from Aethlon Medical.

In a nutshell, it is my 2 cents that the Aethlon Medical’s hemouprifier is going to become the most valuable medical device for mankind.  Needless to say, I added more shares after $AEMD retraced back to low $1.xx when fear of dilution came into the picture.  As far as I’m concerned, once efficacy is proven as a valid adjunct to standard of care for metastatic cancer (where most of the patients actually recovered), $AEMD will just keep on going up and up because institutions will be buying it up.

$IBIO – iBio will be sharing the success of Aethlon Medical’s hemopurifier when it comes since it is the leading supplier of the hemopurifier bio-materials.  Also, I’m expecting to hear news regarding the filing of IND for its lead therapeutic candidate- IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases.  According to their FWP SEC filing on June 13, 2018, Phase I for IBIO-CFB03 should be initiated before year-end.


$LRAD – Its superior mass notification system is why I’m betting on this one.  It is my 2 cents the increased occurrence of natural disaster will necessitate the need to upgrade the legacy bull-horn mass notification system to one that could reach much further with superior voice clarity to save lives.

$SOLO – Solo has an announcement this week, “Electra Meccanica Partners with Dobson Motorsport to Market the SOLO EV in the Pacific Northwest.” To sum it up, below excerpt highlighted the key player behind Dobson Motorsport: SOLO_Dobson

In a nutshell, when Dominic Dobson is willing to use his hard-earned reputation to back Solo EV, it further emphasizes the opinion that single-seat EV is ready for prime time.  At the same time, doubters who do not believe that Zongshen can deliver the Solo in 2019 needs to ask themselves this question, “why would Jerry Kroll get Dominic Dobson to help market the Solo if he thinks Zongshen cannot deliver the Solo?”  In other words, I expect to see the first batch of Solo to arrive very soon in 2019.  It is an exciting time here!

This week my port gave back a bit.

Current positions (in alphabet order):

AEMD  CGC  IBIO  LRAD  MMNFF  SOLOW & cash (up 7.9% YTD)

My 2 cents

From my camera:




Categories: Daily trading Journal, trading journal

Tags: , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: